Macrolide-resistant strains of \textit{Mycoplasma genitalium} are an increasing problem throughout the world, and the implementation of a rapid and sensitive assay for mutation detection to guide treatment is needed. Macrolide-resistant strains have been shown to contain base substitutions in positions 2058 and 2059 (\textit{Escherichia coli} numbering) in region V of the 23S rRNA gene. In this study, we present a SimpleProbe PCR followed by melting curve analysis to differentiate between macrolide-resistant mutants and wild types. The assay was performed on 159 \textit{Mycoplasma genitalium}-positive samples, and the results were compared with DNA sequencing. We also looked at the prevalence of macrolide-resistant strains in a Norwegian population. Of 139 samples characterized successfully by sequencing, 54 (39%) were wild types and 85 (61%) were mutants, consisting of 59 (42%) A2059G, 24 (17%) A2058G, 1 (1%) A2058T, and 1 (1%) A2059C mutation. The melting curve analysis correctly differentiated between wild-type and mutant strains in all cases, but it could not identify the different mutant types. The SimpleProbe PCR proved to be a simple, rapid, and reliable method for the detection of macrolide-resistant isolates of \textit{Mycoplasma genitalium} in a clinical setting.

\textit{Mycoplasma genitalium} is a small bacterium with the ability to cause urethritis in men and women, cervicitis, and pelvic inflammatory disease (PID) in women (1–3). The recommended treatment for urethritis when the infectious agent is unknown (often called nonchlamydial-nongonococcal urethritis, or NCNGU) is 7 days of doxycycline (100 mg twice daily) (4) or 1 g azithromycin given as a single dose (5). The preferred treatment for uncomplicated infection with \textit{M. genitalium} in Scandinavia is 1.5 g azithromycin given over a period of 5 days, where 500 mg is given on day 1 and 250 mg is given on days 2 to 5 (4, 6). This prolonged treatment is preferred to avoid development of macrolide resistance (7). Recent studies show the emergence of resistant types of \textit{M. genitalium} in many parts of the world (8–10). The most common mutations causing macrolide resistance are found in domain V in the 23S rRNA gene (11). A2058G and A2059G are the most common mutations reported, followed by A2058T and A2058C (10, 12). The second-line antibiotic following treatment failure with azithromycin is moxifloxacin, a fluoroquinolone (6). However, several reports of resistance to this group of antibiotics have also been published (13, 14).

With increasing prevalence of resistant strains, access to the assessment of macrolide sensitivity becomes important. The gold standard for detecting mutations in the 23S rRNA region is DNA sequencing, but the method is too laborious, time-consuming, and expensive for routine analysis. Touati et al. presented a real-time PCR using fluorescence resonance energy transfer (FRET) combined with melting curve analysis (15) to detect mutations. Twin et al. utilized high-resolution melting curve analysis (16). Wold et al. presented a method using PCR with a TaqMan probe and polymorphism-specific forward primers (17), although only for specimens that had a cycle threshold ($C_T$) of less than 32, thereby excluding samples with a lower organism load. PCR followed by pyrosequencing has also been presented (12), and recently, Kristiansen et al. presented a 5’-nucleotide genotyping assay for this purpose (18).

The method presented in this study is a SimpleProbe real-time PCR followed by melting curve analysis. This method uses a single probe labeled with a self-quenching fluorophore (19). Different mutations in the gene segment cause different melting temperatures and enable differentiation between wild-type and mutant strains.

Our aim was to develop a simple and sensitive method for diagnostic use to differentiate between the macrolide-susceptible wild type and mutant types of \textit{M. genitalium} without the need for nucleotide sequence determination. The method has been used for the detection of other microbes (20, 21) but, to our knowledge, has never been applied to \textit{M. genitalium} mutation detection. The study also aimed to present the prevalence of macrolide-resistant \textit{M. genitalium} isolates in a Norwegian population.
MATERIALS AND METHODS

Sample collection and primary screening. M. genitalium-positive samples were collected from the Department of Medical Microbiology at St. Olav’s Hospital, Norway, between February 2015 and May 2015. The majority of specimens came from outpatients not attending sexually transmitted disease clinics. Samples had undergone DNA extraction and primary testing within 3 days after sampling before being frozen. All samples were obtained for study purposes and analyzed by SimpleProbe PCR in June 2015. DNA sequencing analysis were performed during the period September to November 2015. Primary screening was performed using a CFX96 real-time system C1000 thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA) and FTD urethritis basic kit (Fast-Track Diagnostics Ltd., Esch-sur-Alzette, Luxembourg) for the simultaneous and quantitative detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and M. genitalium. The FTD urethritis basic kit is a multiplex real-time PCR with probes targeting the adhesin (mgmB) gene of M. genitalium, the cryptic plasmid ORF8 gene of Chlamydia trachomatis, and the opak gene for the opacity protein of Neisseria gonorrhoeae. Murine cytomegalovirus is used as an internal control and detected by a probe targeting an intergenic region of this virus. The sensitivity of the M. genitalium assay is approximately 1,000 copies/ml according to the manufacturer. After excluding test-of-cure samples taken within 3 months and samples taken from different locations on the same patient, 159 primary samples were included in this study (Table 1). When samples taken from more than one location on the same patient were present, cervical swabs were preferred over vaginal swabs, vaginal swabs were preferred over urethral swabs, and urethral swabs were preferred over urine samples. The samples comprised 65 voided urine samples (FVU) from men and 94 flocked swabs (88 swabs from women and 6 urethra swabs from men) in universal transport medium (UTM; Copan Italia S.P.A., Brescia, Italy). Swabs obtained from women were either vaginal (65%) or endocervical (35%). DNA was extracted from 1 ml urine and 200 μl transport medium from swabs using NucliSens easyMAG (bioMérieux SA, Marcy l’Etoile, France). The manufacturer of the kit provided a validated formula for the direct quantification of the organisms detected in the samples. Extracted DNA was stored at −20°C until further processing. Wild-type G37 and strains with A2058G, A2058T, A2058C, and A2059G mutations were kindly provided by J. S. Jensen (Statens Serum Institut, Copenhagen, Denmark).

SimpleProbe real-time PCR and melting curve analysis. The reaction mixture for each sample consisted of 10 μl SoAdvanced universal probe supermix (Bio-Rad Laboratories Inc., Hercules, CA, USA), 1 μl of forward primer Mg235S (2 μM), 1 μl of reverse primer Pr f Sp mis (10 μM), 1 μl SP wild-type probe (10 μM; TIB Molbiol, Berlin, Germany), 2 μl molecular-grade water, and 5 μl DNA template. Primers and probe sequences were presented in Table 2. The amplification commenced at a single step of 95°C for 3 min, followed by 50 cycles at 95°C for 15 s and 55°C for 30 s, using a CFX96 real-time system C1000 thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA). After amplification, the melting curve analysis started at 45.0°C and ended at 75.0°C, with an increment of 0.5°C every 5 s. The sensitivity of the SimpleProbe assay was calculated to 6 copies per PCR using a 10-fold dilution series of AmpliRun Mycoplasma genitalium DNA control (Vircell, Granada, Spain) at 12,500 copies/μl.

| Parameter | Male | Female | Total |
|-----------|------|--------|-------|
| No. of samples | 71 | 88 | 159 |
| Median age (yr; range) | 28 (16–54) | 24 (17–64) | 26 (16–64) |

DNA sequence determination. To determine the 23S RNA gene sequences, all samples were DNA sequenced after melting curve analysis. Amplification prior to sequencing was performed by a T100 thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA) with the same reaction mixture as that for the SimpleProbe real-time PCR, excluding the probe at an annealing temperature of 63°C. The higher annealing temperature reduces unspecific amplification in a mixture where there is no probe, as the specific binding of the probe in the SimpleProbe reaction helps to ensure specific detection at a lower annealing temperature. The analysis of the size of the amplicon and DNA concentration was performed using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA), and product cleanup was achieved with a rapid PCR cleanup enzyme set (New England Biolabs Inc., Ipswich, MA, USA). A GenomeLab DTCS quick start kit (Beckman Coulter Inc., Brea, CA, USA) was used for dye terminator cycle sequencing of the 241-bp amplification from the 23S RNA gene with the forward primer Mg235 S. The sequence products were analyzed by a CEQ8800 genetic analysis system (Beckman Coulter Inc., Brea, CA, USA). The reac-

| Primer name | Sequencea | Gene sequence position |
|-------------|-----------|------------------------|
| Forward primer | 5’-GGTTAAAGAGGGAGTCTACATT-3’ | 1850–1874 |
| Reverse primer | 5’-AGCTACGTTAAGGATCTGG-3’ | 2090–2068 |
| SP wild-type probe | 5’-CGCA-XI-ACGGGACGGAGAACCC-3’ | 2050–2069 |

a The reverse primer intentionally contains one mismatch to avoid GAGGGG (under the probe) and CCCGT (at the 3’ end of the primer). The calculated melting temperature for the folded structure is 84°C. The folded PCR product will compete with probe binding and cause low signals and secondary lower melting temperature peaks. XI in the probe sequence is the position of d-inosine as a non- or low-binding base moiety.

RESULTS

Test sensitivity. In the primary screening test, the range of the bacterial load from swabs and urine samples was 3.39 × 105 to 1.51 × 107 copies/ml (median, 8.47 × 105 copies/ml) and 5.87 × 105 to 2.40 × 106 copies/ml (median, 1.34 × 105 copies/ml), respectively. The sensitivity of the genotyping methods is shown in Table 3, where the lowest bacterial load in specimens yielding a successful melting curve analysis and sequencing results are listed. Of the 159 patients with M. genitalium-positive samples that later underwent both SimpleProbe PCR analysis and DNA sequencing, 17 (11%) were negative by both methods. Of the remaining 142 samples, 139 were positive in SimpleProbe PCR and 139 yielded a positive result when DNA was sequenced. Six samples yielded positive results in only one of the two tests, and 136 samples were positive by both tests. The kappa value was 0.91 (with 95% CI of
TABLE 3 Lowest bacterial load in swab and urine specimens yielding a successful melting curve analysis and DNA sequencing result

| Assay              | Bacterial load (copies/ml) by sample typea |
|--------------------|------------------------------------------|
|                    | Swab | Urine  |
| SimpleProbe PCR    |       |        |
| Lowest copy no. yielding a positive result | $6.99 \times 10^2$ | $1.31 \times 10^2$ |
| Lowest copy no. when all samples with higher bacterial load yielded a positive result | $5.99 \times 10^3$ | $1.31 \times 10^2$ |

DNA sequencing

| Lowest copy no. yielding a positive result | DNA sequencinga |
|------------------------------------------|-----------------|
|                                           |                 |
| Lowest copy no. when all samples with higher bacterial load yielded a positive result |                 |

a All swabs containing more than $5.99 \times 10^3$ copies/ml and all urine samples containing more than $1.31 \times 10^3$ copies/ml yielded a positive result by the SimpleProbe assay. The corresponding results for the DNA sequencing were $5.99 \times 10^3$ copies/ml and $7.98 \times 10^3$ copies/ml, respectively.

0.74 to 1.08). Among the 136 specimens with positive results, five samples had no amplification curve in the SimpleProbe assay. However, melting curve analysis could be interpreted, and the result correlated with the DNA sequencing. The test sensitivity for both methods was 87% (CI, 0.817 to 0.923).

Melting curve analysis. The wild types had a melting temperature ranging between 64°C and 65°C, whereas the mutants had melting temperatures ranging between 57°C and 59°C (Fig. 1). Samples with a high $C_T$ value from the routine testing had a tendency toward higher melting temperatures, but all were within the given range.

Distribution of M. genitalium 23S rRNA mutations. Of the successfully DNA sequenced samples, there were 54 (39%) wild types and 85 (61%) mutants (Table 4). Four types of mutations were present: 59 A2059G (69%), 24 A2058G (28%), 1 A2059C (1%), and 1 A2058T (1%). Melting curve analysis and sequencing results for the 136 samples that were positive by both methods showed complete concordance with each other (Table 4). Sequencing data contained no evidence that multiple templates were present in any of the samples.

DISCUSSION

In this study, we report a large number (61%) of patient samples with mutations in region V of the 23S rRNA gene of M. genitalium.

The most commonly reported mutations to cause macrolide failure (11, 12), A2059G and A2058G (12, 16, 17), represented 42% and 17%, respectively, of the 139 positive samples. We also report the presence of the less common mutations A2059C and A2058T. A2059C has been reported in Australia (16), France (23), and England (8), but to our knowledge it has not been reported in Scandinavia before.

The range of the bacterial load from swabs was $3.39 \times 10^2$ to $1.51 \times 10^2$ copies/ml and $5.87 \times 10^3$ to $2.40 \times 10^3$ copies/ml for the urine samples in the primary screening. The better sensitivity for the urine samples correlates well with the fact that the DNA extraction volume was five times larger for the urine samples (1,000 μl) than the swab specimens (200 μl).

In this study, there was a complete correlation between the SimpleProbe assay and DNA sequencing for 136 (86%) of the samples. Kappa analysis of the two methods gave a score of 0.91 (95% CI, 0.74 to 1.08), indicating a strong agreement of the two methods. The remaining 23 (14%) samples were negative in either one or both tests, but none yielded contradictory results. All samples had been frozen and thawed between every set of processing. Hence, the quality of the DNA in the samples may have been reduced after the first PCR run (24). Five of the positive samples had no amplification curve in the SimpleProbe PCR but had a melting curve that correlated with the sequencing results. A possible explanation for this is that for the SimpleProbe assay, the annealing temperature at 55°C had been optimized with respect to the melting curve analysis, whereas the annealing temperature in the conventional PCR prior to the sequencing reaction had been optimized to 63°C. These samples were probably at the limit of detection for the method, and it is likely that with a few more amplification cycles we would have achieved an amplification curve. This optimization of annealing temperatures might also explain the reason why three samples turned out negative in the SimpleProbe assay but positive when DNA was sequenced. All specimens with a bacterial load of more than 6,000 copies/ml in the primary screening test were positive in both the SimpleProbe assay and by DNA sequencing.

The melting temperature of the macrolide-resistant strains varied between 57°C and 59°C. However, the differences between the melting temperatures of these strains were too small to distinguish between the different mutations. In addition to having overlapping melting temperatures, the individual samples could vary by 0.5°C from run to run. The mutants were, however, easy to distinguish from the wild types, with melting temperatures of 64 to 65°C. Therefore, DNA sequencing was the method of choice to distinguish the different mutant types from each other. We observed that the melting temperature had a tendency to be higher as the sample concentration decreased (higher $C_T$ values). The defi-
tion of melting temperature is when 50% of the opposing strands are dissociated, and it is possible that bacterial concentration influences this balance.

Some researchers have reported urine samples to have higher sensitivity than urethral swabs from males for the detection of *Chlamydia trachomatis* and *M. genitalium* (25), and this practice is recommended by the Norwegian Institute of Public Health (26). This is the reason for the small number of urethral swabs evaluated, as urethral swabs from males in our health region usually are collected only in cases where infection with *Neisseria gonorrhoeae* is suspected.

Screening for *M. genitalium* in asymptomatic patients is controversial. The high sensitivity of nucleic acid amplification tests may result in the detection of low-grade infections that have the potential to clear spontaneously or would never cause any harm to the patient (27). Unlike for *Chlamydia trachomatis*, not much is known about the natural history of *M. genitalium*, and as *M. genitalium* is becoming increasingly harder to treat, the cost versus benefit of screening needs to be considered carefully. Macrolide sensitivity than urethral swabs from males for the detection of low-grade infections that have the potential to clear spontaneously or would never cause any harm to the patient (27).

**REFERENCES**

1. Taylor-Robinson D, Jensen JS. 2011. Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 24:498–514. http://dx.doi.org/10.1128/CMR.00006-11.

2. Caranave C, Manhart LE, Bebear C. 2012. Mycoplasma genitalium, an emerging sexually transmitted pathogen. Med Mal Infect 42:381–392. http://dx.doi.org/10.1016/j.medmal.2012.05.006.

3. Daley G, Russell D, Tabrizi S, McBride J. 2014. Mycoplasma genitalium: a review. Int J STD AIDS 25:475–487. http://dx.doi.org/10.1017/S0956462413515190.

4. Moi H, Blek K, Horner PJ. 2015. Management of non-gonococcal urethritis. BMC Infect Dis 15:294. http://dx.doi.org/10.1186/s12879-015-1043-4.

5. Workowski KA, Bolan GA. Centers for Disease Control and Prevention. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:1–137. http://dx.doi.org/10.15585/mmwr.r6404a1.

6. Manhart LE, Broad JM, Golden MR. 2011. Mycoplasma genitalium: should we treat and how? Clin Infect Dis 53(Suppl 3):S129–S142. http://dx.doi.org/10.1093/cid/cir702.

7. Weinstein SA, Stiles BG. 2012. Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium. Expert Rev Anti Infect Ther 10:487–499. http://dx.doi.org/10.1586/eri.12.20.

8. Pond MJ, Nori AV, Witney AA, Lopeman RG, Bechar PD, Sadiq ST. 2014. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis 58:631–637. http://dx.doi.org/10.1093/cid/cit752.

9. Tagg KA, Jeffreys NJ, Couldwell DL, Donald JA, Gilbert GL. 2013. Fluoroquinolone and macrolide resistance-associated mutations in *Mycoplasma genitalium*. J Clin Microbiol 51:2245–2249. http://dx.doi.org/10.1128/JCM.00495-13.

10. Nijhuis RH, Severs TT, Van der Vegt DS, Van Zvet AA, Kusters JG. 2015. High levels of macrolide resistance-associated mutations in *Mycoplasma genitalium* warrant antibiotic susceptibility-guided treatment. J Antimicrob Chemother 70:2515–2518. http://dx.doi.org/10.1093/jac/dkv136.

11. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. 2008. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis 47:1546–1553. http://dx.doi.org/10.1086/593188.

12. Salado-Rasmussen K, Jensen JS. 2014. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis 59:24–30. http://dx.doi.org/10.1093/cid/ciu217.

13. Bisssicor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, Vodstrcil LA, Jensen JS, Hocking JS, Garland SM, Bradshaw CS. 2015. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis 60:1228–1236. http://dx.doi.org/10.1093/cid/ciu162.

14. Couldwell DL, Tagg KA, Jeffreys NJ, Gilbert GL. 2013. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS 24:822–828. http://dx.doi.org/10.1258/ijstd.2011.011591.

15. Touati A, Peuchant O, Jensen JS, Bebear C, Pereyre S. 2014. Direct detection of macrolide resistance in *Mycoplasma genitalium* isolates from clinical specimens from France by use of real-time PCR and melting curve analysis. J Clin Microbiol 52:1549–1555. http://dx.doi.org/10.1128/JCM.03318-13.

16. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, Tabrizi SN. 2012. Transmission and selection of macrolide resistant *Mycoplasma genitalium* infections detected by rapid high resolution melt analysis. PLoS One 7:e35593. http://dx.doi.org/10.1371/journal.pone.0035593.

17. Vold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N. 2015. Identification of macrolide-resistant *Mycoplasma genitalium* using real-time PCR. J Eur Acad Dermatol Venereol 29:1616–1620. http://dx.doi.org/10.1111/jdv.12963.

18. Kristiansen GQ, Lishy JG, Schonning K. 2016. A 5’ nucleotide genotyping assay for identification of macrolide-resistant *Mycoplasma genitalium* in clinical specimens. J Clin Microbiol 54:1593–1597. http://dx.doi.org/10.1128/JCM.00012-16.

19. Klaassen CH, van Aarsen YA, van der Steppen JW. 2008. Improved real-time detection of the H63D and S65C mutations associated with hereditary hemochromatosis using a SimpleProbe assay format. Clin Chem Lab Med 46:985–986.

20. Kondiah K, Swanepoel R, Pawsa JA, Burt FJ. 2010. A SimpleProbe real-time PCR assay for genotyping resorted and non-resorted isolates of Crimean–Congo hemorrhagic fever virus in southern Africa. J Virol Methods 169:34–38. http://dx.doi.org/10.1016/j.jviromet.2010.06.010.

21. Kengkate M, Butteph P, Kupatawintu P, Sirussudee A, Chantratita W, Nathalang O. 2015. Comparison of a simple-probe real-time PCR and multiplex PCR techniques for HPA-1 to HPA-6 and HPA-15 genotyping. J Clin Lab Anal 29:94–99. http://dx.doi.org/10.1002/jcla.21734.
22. Vester B, Douthwaite S. 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 45:1–12. http://dx.doi.org/10.1128/AAC.45.1.1-12.2001.
23. Chrisment D, Charron A, Cazanave C, Pereyre S, Bebear C. 2012. Detection of macrolide resistance in Mycoplasma genitalium in France. J Antimicrob Chemother 67:2598–2601. http://dx.doi.org/10.1093/jac/dks263.
24. Carlsen KH, Jensen JS. 2010. Mycoplasma genitalium PCR: does freezing of specimens affect sensitivity? J Clin Microbiol 48:3624–3627. http://dx.doi.org/10.1128/JCM.00232-10.
25. Jensen JS, Bjornelius E, Dohn B, Lidbrink P. 2004. Comparison of first void urine and urogenital swab specimens for detection of Mycoplasma genitalium and Chlamydia trachomatis by polymerase chain reaction in patients attending a sexually transmitted disease clinic. Sex Transm Dis 31:499–507. http://dx.doi.org/10.1097/01.olq.0000135992.98883.e4.
26. Blystad H. 2015. Mykoplasmainfeksjon, genital-veileder for helsepersonell. Norwegian Institute of Public Health, Oslo, Norway. http://www.fhi.no/artikler/?id=82826.
27. Aavitsland P. 2016. Screening for Mycoplasma genitalium infection? Tidsskr Nor Laegeforen 136:104. http://dx.doi.org/10.4045/tidsskr.16.0038.
28. Oliphant CM, Green GM. 2002. Quinolones: a comprehensive review. Am Fam Physician 65:455–464.
29. Kikuchi M, Ito S, Yasuda M, Tsuchiya T, Hatazaki K, Takanashi M, Ezaki T, Deguchi T. 2014. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother 69:2376–2382. http://dx.doi.org/10.1093/jac/dku164.